Related references
Note: Only part of the references are listed.Successful Erlotinib Rechallenge after Gefitinib-Induced Acute Interstitial Pneumonia
Shih-Chieh Chang et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non-Small Cell Lung Cancer with EGFR Mutations
Satoshi Morita et al.
CLINICAL CANCER RESEARCH (2009)
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
K. Tamura et al.
BRITISH JOURNAL OF CANCER (2008)
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Daniel B. Costa et al.
CLINICAL CANCER RESEARCH (2008)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors
L. V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy
Noriaki Sunaga et al.
LUNG CANCER (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer
Kimihide Yoshida et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
H. Asahina et al.
BRITISH JOURNAL OF CANCER (2006)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
MG Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
M Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)